| WHAT IS K NOWN AND OBJEC TIVE
The increasing age of the population is a success of individual and public health that unfortunately goes hand in hand with multimorbidity and polypharmacy. Of specific concern are prescription and over-the-counter medications that have anticholinergic activity. These include a wide variety of drugs including those for hypertension, cardiovascular and pulmonary disease. Over the last 25 years, there has been increasing evidence that cholinergic blockade in the central nervous system has been linked to adverse effects such as confusion, behavioural disturbances, reduced executive and motor functions, altered emotions [1] [2] [3] [4] [5] and increased risk of falls, delirium, chronic cognitive impairment and mortality. [6] [7] [8] [9] An age-related increase in permeability of the blood-brain barrier is thought to contribute to this problem. 10 The use of multiple drugs with drugs with anticholinergic properties (DAPs) is thought to have an additive effect. The cumulative anticholinergic cognitive burden (ACB) of all therapies predicts more accurately the risk of adverse events. 11 Acetylcholinesterase inhibitors (AChE-I) are used in the treatment of mild-to-moderate Alzheimer's disease.
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Up to 60% of patients with dementia are reported to receive at least one anticholinergic drug. 13, 14 The combination of both proand anticholinergics can elicit an antagonistic response and further hasten cognitive decline.
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Review and optimization of medication are recommended by specialist representative bodies. 16 The widely used STOPP/START criteria for potentially inappropriate prescribing in older people were expanded in the latest version of 2014 to cover more drugs that have anticholinergic activity. 17 The 2015 revision of the Beer's criteria by the American Geriatric Society recommends avoiding anticholinergics in patients with chronic cognitive impairment and delirium. The Silver Book by the British Geriatric Society defines standards for urgent and emergency care of frail older patients and advocates a medicines review at the time of crisis, with particular regard to sedative, psychotropic, hypotensive or anticholinergic medications.
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Little is known about how effective the recommended review of DAPs is in patients at risk who present acutely and how often drugs with anticholinergic properties are used temporarily during an admission. We investigated the impact of hospital admission on the anticholinergic burden and the use of relevant medications in medical patients admitted with a diagnosis of delirium, chronic cognitive impairment or falls. As such, our main objective was to investigate the possible change of the ACB from admission to discharge and the temporary use of DAPs. The secondary goal was to identify differences in diagnostic and demographic subgroups including death and readmission.
| ME THODS
This multicentre observational study, which took place between Each centre selected patients prospectively over a period of at least 1 month. We included unscheduled emergency admissions under the medical teams (ie, acute medicine, general internal medicine and geriatric medicine) with a diagnosis of chronic cognitive impairment or dementia, acute confusional state or delirium, or falls.
We recorded demographics, date of admission, diagnoses that led to inclusion in the study, use of AChE-Is, whether a new diagnosis of dementia had been made by discharge, the date of discharge or death, and whether patients were readmitted or died within 30 days after discharge. To record DAPs, we adapted the 2012 revision of the original ACB scale. 22 Medication names were translated to those in use in the participating centres and were grouped by indication and ACB. We added the opioid tramadol due to its central type-3 muscarinic receptor antagonism. 23 The relevant medications, as well as each patient's cumulative burden on admission and discharge and if used during the hospital stay, were recorded ( Figure 1 ).
We compared demographic subgroups, diagnoses, length of stay (day 0 discharge, short stay of up to 3 days, stay up to 1 week and stay 
| RE SULTS AND D ISCUSS I ON
The baseline characteristics of the 549 patients included are summarized in Table 1 Table 2b ).
Of 98 medications on the ACB scale, 56 were observed in our patients. were recorded on admission. These represent 13.8% of all recorded
Number of patients 549
Male (%) 41.7
Mean age (years) 79.6
Patients aged 65 years or older 89.8%
Admission diagnosis:
Acute delirium (%) 34.8
Dementia diagnosed during admission (%) 4.9
Patients on anticholinergics (%) 60.8
Patients on cholinesterase inhibitors (%) 6.7
Mean length of stay (days) 9.3
30-day readmission rate as % of all patients 15.7
As % of all patients that were discharged/survived 16.9
Mortality during index admission in % 7.7
Mortality within 30 days post-discharge in % 4.0
The data sets were complete for all but 5 patients (0.9%) where follow-up information was unavailable.
drugs used or 31.9% of the anticholinergic burden. 6.0% of all patients were taking at least one of them. The anticholinergic load in our patients was predominantly caused by medications with a low individual burden which were accounting for 64.9% of the total burden (Table 3) .
DAPs were used temporarily during the admission in 21.9% of all patients. Their mean ACB score was low at 0.4 (range 0-6, SD 0.9).
We found 26 different medications, most frequently morphine, codeine, haloperidol, diazepam and furosemide (Table 4) .
Tramadol, which we had added in our adaption of the ACB scale, was only seen in 2.7% of patients on admission and was used temporarily in 2.9%.
The results of our subgroup analysis are shown in Tables 5a-d.
Short stay patients (stay for a maximum of 3 days) were the only group that saw their ACB reduced (P = .018, Table 5d ). This group had fewer patients on DAPs on discharge (48.4% vs 60.5%, P = .022), saw equal numbers of patients who had their anticholinergics reduced but fewer patients who had theirs increased (8.9%
vs 22.8%, P = .001) compared to the patients who were not short stay.
Patients who could not return home but were discharged to sheltered accommodation, residential or nursing home, were older than the rest of the patients (82.0 vs 76.5 years, P < .001) but did not differ in ACB scores. They were the only subgroup which saw a significant increase in ACB by discharge (P = .016, Table 5d ). More than double of these patients had their ACB increased (15.4 vs. 32.7%, P < .001), and they also saw a much higher temporary use of DAPs (in 34.6% vs 16.4% of patients, P < .001) with a higher burden of anticholinergics used temporarily (mean 0.7, SD 1.2 vs mean 0.2, SD 0.6, P < .001) compared to those who went back home. 
TA B L E 2 (Continued)
F I G U R E 2 Medications with anticholinergic properties in all patients on admission and discharge
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F I G U R E 3
Medications with anticholinergic properties in all patients on admission and discharge, weighted by their individual anticholinergic burden Men in our study were younger than women (mean 77.7 vs.
81.0 years, P = .003) and were more likely to be prescribed temporary anticholinergic drugs (26.6% vs. 18.1%, P = .022, Table 5a ) with a higher burden of anticholinergics used temporarily (mean 0.5, SD 1.1 vs mean 0.3, SD 0.7 P = .004).
Patients who died during index admission as well as those who were readmitted or died within the 30-day follow-up period did not differ from the rest of the patients in ACB on admission or discharge/death (Table 5d ). Those who died had a smaller proportion of patients on DAPs at death. Our data do not allow us to differentiate between expected and unexpected deaths, though it is likely that this reduction in number of patients may be due to the deliberate stopping of medications in those who were not able to take them anymore or who had been commenced on an end of life care pathway.
Prescribing behaviour in all diagnostic subgroups of dementia, delirium or falls, as well as in those with newly diagnosed dementia, was similar with no statistically significant change in ACB scores or number of patients on anticholinergic drugs, as well as with regard to the temporary use of drugs with anticholinergic properties (Table 5b ). Figure 4 shows the distributions of anticholinergic burden in each of the diagnostic groups on admission and discharge.
AChE-I (Table 5b ) was found on admission in 18.2% of patients with a diagnosis of chronic cognitive impairment (or in 6.7% of all patients). Of these patients on procholinergics, 54.1% were also taking DAPs. This subgroup did not differ from the rest with regard to the number of patients on DAPs, ACB scores or the number of naïve patients newly started on DAPs (Table 5c ). 25 The resulting prescribing of anticholinergics will offset their efficiency and may hasten cognitive decline.
The use of drugs with the highest anticholinergic burden was low amongst our patients, and the anticholinergic load was caused predominantly by drugs with lesser activity. Adverse drug events are the result of the anticholinergic load of multiple medications rather than of a single drug. 26 Combined anticholinergic use increases hospitalizations and mortality in older people 27 and hastens cognitive decline. For one point in the ACB, a decline in the Mini-mental State Examination 28 (MMSE) score of 0.33 over 2 years has been suggested. 7 Furthermore, an increase in the cumulative ACB by one has been linked with a 26% increase in mortality.
29
More than one-third of medications included in the ACB scale were not in use in our patients. This reflects the availability of these medications within the countries that took part in our study. In a globalized world with access to non-formulary drugs when travelling abroad or by purchasing them online via regulated or rogue pharmacies, we do not suggest the use of a shortened ACB scale.
Temporary medications were used in more than 1 in 5 patients.
This was the same in all diagnostic subgroups including patients with an acute delirium, potentially worsening their confusion. It may be difficult to fully avoid these but non-pharmacological approaches to prevent or treat delirium including addressing the environment in which patients are cared for may reduce their need.
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Our study is not without limitations. Our aim was to analyse the impact of an acute admission on the anticholinergic burden.
We did not record comorbidities and did not identify terminally ill patients or those with end-stage dementia. Overall, rates for readmission and mortality were nevertheless similar to those in patients described in large cohort studies looking at outcomes of elderly patients admitted. 31 All participating centres were acute hospitals either at regional or at teaching hospital level. We did not look into potential differences of the organization of medication management in these facilities. The clinicians involved in the project were also-at least in part-the same clinicians looking after the patients included in our study. These factors may have potentially also accounted for the regional differences highlighted by the regression analysis, that is that for patients recruited in UK or Finnish centres, the probability for an increase in ACB score was lower. Studies comparing the organization of medicines review and optimization in different healthcare systems will be necessary to investigate this in future.
TA B L E 5 (a) Gender, (b) diagnoses, (c) patients on cholinesterase inhibitors (AChE-I) and (d) other subgroups
Our results mirror community-based studies that have shown that there is considerable scope for improvement of prescribing practices in older people. 14 Theoretical models have shown that a reduction in anticholinergic burden can be achieved in 59% of patients that score at least one point on the ACB scale and that a reduction from a score of 3 or above to 2 is possible in 85% of the cases. 
| WHAT IS NE W AND CON CLUS I ON
To our knowledge, this is the first multicentre study to investigate the effect of an acute admission on the ACB. There was no reduction in cumulative scores in our patients who presented as unscheduled emergency admissions with a history of falls, acute delirium or dementia.
Similar numbers of patients had their ACB reduced or increased. The same medications, whilst stopped in some patients, were started in others. More than one in 5 patients who were not taking anticholinergics when admitted were prescribed them by discharge. This prescribing pattern was the same for all diagnostic subgroups. Short-stay patients had their ACB burden reduced by discharge. In contrast, patients who
were not able to be discharged back to their home were the only subgroup identified which saw a significant increase in ACB from admission to discharge. Despite more than 25 years of evidence and national as well as international recommendations, much more needs to be done to improve medication management in these patients. "Imperative drugging -the ordering of medicine in any and every malady is no longer regarded as the chief function of the doctor" but "one of the first duties of the physician is to educate the masses not to take medicines." 35, 36 These quotes by Sir William Osler are even more valid today, nearly a century after his death. To substantiate them will require a joint effort from both primary and secondary care, through more education, more focused involvement from pharmacists and multidisciplinary teams, both in the community and in hospitals, and also by raising awareness in patients, their caregivers and support groups alike.
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